Amiodarone’s Effect on Teneligliptin Pharmacokinetics in Animal Models

Abstract

Heart arrhythmia and diabetes management has become increasingly difficult in recent years. Type 2 diabetes (T2DM) is on the rise, and it's accompanied by a host of complications. T2DM patients are commonly treated with a variety of medications, raising the possibility of dangerous drug interactions (DDIs). Drug interactions have an effect on the cytochrome (CYP) enzymes, absorption properties, transporter activity, and receptor affinities of the body. CYP enzymes, absorption characteristics, transporter activity, and receptor affinities are all affected by pharmacokinetic/pharmacodynamic interactions. Pharmacokinetic interactions account for the great majority of clinically relevant interactions since the cytochrome P450 enzyme system is responsible for the metabolism of the majority of antiarrhythmics. Antiarrhythmics may be substrates, inducers, or inhibitors of cytochrome P450 enzymes, according to research. A frequent application of amiodarone is to treat heart arrhythmias is to treat them with an anti-arrhythmic medication. Amiodarone is metabolised by CYP450 enzymes and isoenzymes such CYP3A4 and CYP2C9. A strong CYP3A4 and CYP2C9 isoenzyme inhibitor, amiodarone is used to treat heart failure. Teneligliptin, for example, is metabolised by CYP3A4 isoenzymes. As a result, it's possible that amiodarone and teneligliptin will interact. Studies using amiodarone and teneligliptin in DDIs have not been released yet.. nevertheless As a result, this research was designed to better understand the potential drug-drug interaction (DDI) between amiodarone and teneligliptin.